Pleiotropic effects of statin therapy: molecular mechanisms and clinical results

Trends in Molecular Medicine

Volumn 14, Issue 1, 2008, Pages 37-44

  Wang, Chao Yung ^a   Liu, Ping Yen ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPID; MEVINOLIN; PLACEBO; PRAVASTATIN; PROTEIN CDC42; PROTEIN KINASE B; RAC PROTEIN; RHO FACTOR; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; PROTEIN EXPRESSION; REVIEW;

CHOLESTEROL; GTP-BINDING PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; TERPENES;

EID: 38049034068     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.11.004     Document Type: Review

References (99)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Sacks F.M., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335 (1996) 1001-1009
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339 (1998) 1349-1357
4. Shepherd J., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333 (1995) 1301-1307
5. Downs J.R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 279 (1998) 1615-1622
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
7. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
8. Van Aelst L., and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 11 (1997) 2295-2322
9. Maurer-Stroh S., et al. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput. Biol. 3 (2007) e66
10. Greenwood J., et al. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6 (2006) 358-370
11. Kivipelto M., et al. Statin therapy in Alzheimer's disease. Lancet Neurol. 4 (2005) 521-522
12. Brouilette S.W., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369 (2007) 107-114
13. Sytkowski P.A., et al. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N. Engl. J. Med. 322 (1990) 1635-1641
14. Cannon C.P., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350 (2004) 1495-1504
15. Archbold R.A., and Timmis A.D. Cholesterol lowering and coronary artery disease: mechanisms of risk reduction. Heart 80 (1998) 543-547
16. Ross R. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med. 314 (1986) 488-500
17. Pinderski L.J., et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90 (2002) 1064-1071
18. Robinson J.G., et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46 (2005) 1855-1862
19. McCarey D.W., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363 (2004) 2015-2021
20. LaRosa J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352 (2005) 1425-1435
21. Node K., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
22. Horwich T.B., et al. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol. 43 (2004) 642-648
23. Foody J.M., et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
24. Go A.S., et al. Statin therapy and risks for death and hospitalization in chronic heart failure. J. Am. Med. Assoc. 296 (2006) 2105-2111
25. Ray J.G., et al. Statin use and survival outcomes in elderly patients with heart failure. Arch. Intern. Med. 165 (2005) 62-67
26. Tavazzi L., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur. J. Heart Fail. 6 (2004) 635-641
27. Kjekshus J., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail. 7 (2005) 1059-1069
28. The Lipid Research Clinics. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Assoc. 251 (1984) 365-374
29. Buchwald H., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. 323 (1990) 946-955
30. Sudhop T., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
31. Bruckert E., et al. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 107 (2003) 3124-3128
32. Landmesser U., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
33. Fichtlscherer S., et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur. Heart J. 27 (2006) 1182-1190
34. Piorkowski M., et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?. J. Am. Coll. Cardiol. 49 (2007) 1035-1042
35. Sena A., et al. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol. 250 (2003) 754-755
36. Vollmer T., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
37. Grundy S.M., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
38. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
39. Uehata M., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
40. Katsumata N., et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β. Circulation 96 (1997) 4357-4363
41. Laufs U., et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102 (2000) 3104-3110
42. Bishop A.L., and Hall A. Rho GTPases and their effector proteins. Biochem. J. 348 (2000) 241-255
43. Burridge K., and Wennerberg K. Rho and Rac take center stage. Cell 116 (2004) 167-179
44. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
45. Shibuya M., et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J. Neurosurg. 76 (1992) 571-577
46. Mallat Z., et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 93 (2003) 884-888
47. Sawada N., et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101 (2000) 2030-2033
48. Farah S., et al. A rho-associated protein kinase, ROKα, binds insulin receptor substrate-1 and modulates insulin signaling. J. Biol. Chem. 273 (1998) 4740-4746
49. Noma K., et al. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J. Am. Coll. Cardiol. 49 (2007) 698-705
50. Nishiyama T., et al. Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion. J. Biol. Chem. 279 (2004) 47311-47319
51. Sordella R., et al. Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 113 (2003) 147-158
52. Hyvelin J.M., et al. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ. Res. 97 (2005) 185-191
53. Higashi M., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 93 (2003) 767-775
54. +/- haploinsufficient mice. Circulation 112 (2005) 2959-2965
55. Nohria A., et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ. Res. 99 (2006) 1426-1432
56. Sundaresan M., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem. J. 318 (1996) 379-382
57. Takemoto M., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108 (2001) 1429-1437
58. Wassmann S., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. 59 (2001) 646-654
59. Gregg D., et al. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am. J. Physiol. Cell Physiol. 285 (2003) C723-C734
60. Hordijk P.L. Regulation of NADPH oxidases: the role of Rac proteins. Circ. Res. 98 (2006) 453-462
61. Janssens S., et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97 (1998) 1274-1281
62. Liao J.K., et al. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ. Res. 68 (1991) 1027-1034
63. Werns S.W., et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 79 (1989) 287-291
64. Steinberg D., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320 (1989) 915-924
65. Liao J.K. Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide. J. Biol. Chem. 269 (1994) 12987-12992
66. Alderson L.M., et al. LDL enhances monocyte adhesion to endothelial cells in vitro. Am. J. Pathol. 123 (1986) 334-342
67. Collins T., and Cybulsky M.I. NF-κB: pivotal mediator or innocent bystander in atherogenesis?. J. Clin. Invest. 107 (2001) 255-264
68. Tamai O., et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95 (1997) 76-82
69. Lima J.A., et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 (2004) 2336-2341
70. Anderson T.J., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332 (1995) 488-493
71. O'Driscoll G., et al. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
72. Laufs U., et al. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272 (1997) 31725-31729
73. Essig M., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83 (1998) 683-690
74. Laufs U., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
75. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273 (1998) 24266-24271
76. Plenz G.A., et al. Differential modulation of caveolin-1 expression in cells of the vasculature by statins. Circulation 109 (2004) e7-e8
77. Kureishi Y., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000) 1004-1010
78. Simoncini T., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
79. Yang Z., et al. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100 (1999) 5-8
80. Lerman A., et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325 (1991) 997-1001
81. Hernandez-Perera O., et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ. Res. 87 (2000) 616-622
82. Ichiki T., et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1896-1901
83. Xu C.B., et al. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem. Pharmacol. 64 (2002) 497-505
84. Bourcier T., and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 556-562
85. Huber K., et al. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb. Res. 103 Suppl. 1 (2001) S7-S19
86. Nordt T.K., et al. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb. Haemost. 82 Suppl. 1 (1999) 14-18
87. Mukai Y., et al. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1937-H1942
88. Lee T.S., et al. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110 (2004) 1296-1302
89. Lee T.S., and Chau L.Y. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat. Med. 8 (2002) 240-246
90. Juan S.H., et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 104 (2001) 1519-1525
91. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
92. Kwak B., et al. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
93. Nobes C., and Marsh M. Dendritic cells: new roles for Cdc42 and Rac in antigen uptake?. Curr. Biol. 10 (2000) R739-R741
94. Pahan K., et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100 (1997) 2671-2679
95. Greenwood J., et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17 (2003) 905-907
96. Aprahamian T., et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177 (2006) 3028-3034
97. Youssef S., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
98. Weitz-Schmidt G., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
99. Assmus B., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92 (2003) 1049-1055